glp-1 liver fibrosis Multiple target tissue effects of analogues on non-alcoholic fatty disease (NAFLD) and non-alcoholic steatohepatitis (NASH) Current status of glucagon-like peptide-1

While there's no direct proof that these GLP-1 drugs are driving the drops we're now seeing in obesity rates, given their increasing use and how effective we know they are, it seems likely

doi: 10.1007/s10147-011-0289-0

Semaglutide 0.4 mg once-daily significantly improved NASH compared with placebo (NASH improved in 59% vs 17% of participants)

More of it travels upward instead of downward

Replenza versus Thrive GLP-1 Thrive GLP-1 is another competitor in this space, and comparing the two reveals interesting differences in formulation philosophy and pricing

This makes it difficult to estimate their true prevalence